Welcome to our dedicated page for Milestone Pharmaceuticals SEC filings (Ticker: MIST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Milestone Pharmaceuticals Inc. (MIST) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central to understanding how Milestone reports on its cardiovascular drug programs, financial position, and material corporate events.
For Milestone, current reports on Form 8-K are especially important. Recent 8-K filings describe key milestones such as U.S. Food and Drug Administration approval of CARDAMYST™ (etripamil) nasal spray for adult paroxysmal supraventricular tachycardia (PSVT), acceptance of the company’s response to a Complete Response Letter, new PDUFA target dates, equity offerings, amendments to royalty purchase agreements, and the filing or use of corporate presentations. These filings often incorporate press releases that discuss clinical data, regulatory status, and financing terms in more detail.
Investors can also use this page to locate periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which Milestone references in its news releases. Those documents typically include audited or reviewed financial statements, discussions of research and development and commercial expenses, and risk factor sections addressing uncertainties around regulatory approvals, clinical trials, capital resources, and market conditions.
In addition, Milestone’s capital-raising activities are documented through registration statements and related filings, along with 8-Ks that summarize underwriting agreements, warrant terms, and senior secured convertible notes. These materials explain how the company finances the development and commercialization of CARDAMYST and the broader etripamil program.
On Stock Titan, users can view these filings as they are made available from EDGAR and rely on AI-powered summaries to highlight the main points in lengthy documents, including 10-Ks, 10-Qs, and 8-Ks. The platform also makes it easier to identify items related to topics such as regulatory approvals, financing transactions, and updates on the PSVT and AFib-RVR programs, helping readers navigate Milestone’s disclosure record more efficiently.
Milestone Pharmaceuticals (MIST) filed its Q3 2025 10‑Q. The company reported a net loss of $11.9 million for the quarter and $45.6 million for the nine months. Operating expenses reflected continued R&D and growing commercial preparation, with quarterly R&D of $3.9 million, G&A of $3.3 million, and commercial spend of $4.6 million.
Liquidity strengthened after a July equity and warrant financing, bringing net proceeds of $48.6 million. Cash, cash equivalents and short‑term investments totaled $82.6 million as of September 30, 2025, and management expects liquidity to support operations for at least 12 months. Q3 operating cash outflow was part of year‑to‑date cash used in operations of $36.3 million.
Following a March 2025 Complete Response Letter for CARDAMYST (etripamil) in PSVT, the FDA accepted the company’s resubmission with a PDUFA target date of December 13, 2025. Senior secured convertible notes had a net carrying amount of $56.2 million. Common shares outstanding were 85,169,344 as of September 30, 2025.
Milestone Pharmaceuticals Inc. filed a Form S-8 to register an additional 4,000,000 common shares issuable under its 2019 Equity Incentive Plan, as amended, reflecting shareholder approval of the increase.
The filing incorporates by reference the Registrant's Annual Report for the fiscal year ended December 31, 2024, the Definitive Proxy Statement filed April 30, 2025, Quarterly Reports for the periods ended March 31, 2025 and June 30, 2025, various Current Reports and the Form 8-A description of common stock. Exhibits include amended organizational documents, the amended 2019 EIP, option and RSU award forms, legal opinions and consents.
Milestone Pharmaceuticals reported that it issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing a regulatory and corporate update. The Form 8-K states the press release is attached as Exhibit 99.1 and is incorporated by reference; the filing text itself does not include the numerical results or detailed financial tables. The 8-K also lists the Interactive XBRL cover page file as Exhibit 104 and identifies the disclosure under the Results of Operations and Financial Condition item. Investors are directed to the attached press release for substantive figures and commentary.
Milestone Pharmaceuticals (MIST) delivered a mixed quarterly update focused on advancing its lead candidate, etripamil, while absorbing higher operating losses. For the six months ended June 30, 2025 the company reported a net loss of $33.7 million (net loss per share $0.51) and an accumulated deficit of $401.3 million. As of June 30, 2025, Milestone held $42.5 million in cash and $0.9 million in short-term investments (total ~$43.4 million) and reported total assets of $47.4 million and total liabilities of $65.2 million, including $55.2 million in senior secured convertible notes.
The FDA issued a Complete Response Letter in March 2025 citing CMC and inspection items but accepted Milestone’s June 13, 2025 response and set a PDUFA target date of December 13, 2025. A July 11, 2025 underwritten offering subsequently provided approximately $48.7 million of net proceeds and the RTW royalty agreement marketing deadline was extended to December 31, 2025. NODE-303 data showed a median time-to-conversion of 17 minutes with generally favorable tolerability. The company reported no revenue for the periods presented.